Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Jun 13;121(24):4867-74.
doi: 10.1182/blood-2013-03-490128. Epub 2013 Apr 25.

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Preetesh Jain  1 , Hagop Kantarjian, Aziz Nazha, Susan O'Brien, Elias Jabbour, Carlos Guillermo Romo, Sherry Pierce, Marylou Cardenas-Turanzas, Srdan Verstovsek, Gautam Borthakur, Farhad Ravandi, Alfonso Quintás-Cardama, Jorge Cortes
Affiliations
Clinical Trial

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Preetesh Jain et al. Blood. .

Abstract

Early responses to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)-chronic phase (CP) are associated with improved outcome. We analyzed the impact of such a response on outcomes among patients treated with 4 TKI modalities as frontline therapy in CML-CP. A total of 483 patients who received 400 or 800 mg imatinib, nilotinib, or dasatinib were analyzed. The median follow-up was 72 mo. Landmark analysis at 3 mo by molecular response showed that the cumulative proportions of 3-y event-free survival (EFS) for 3-mo BCR-ABL levels was 95% for those with ≤1%, 98% for >1% to 10%, and 61% for those with >10% (P = .001). The corresponding values by cytogenetic responses were 97% if Ph+ = 0%, 89% if Ph+ = 1% to 35%, and 81% if Ph+ >35% (P = .001). Cytogenetic response at 3 mo significantly discriminated for 3-y overall survival (OS): 98%, 96%, and 92%, respectively (P = .01). In multivariate analysis, young patients, high Sokal index, and treatment with imatinib 400 significantly predicted for poor (>35%) cytogenetic response at 3 mo. Early responses are predictive for EFS and failure-free survival and to a lesser extent OS, regardless of the treatment modality, although therapies other than standard-dose imatinib result in higher rates of deep early responses.

Trial registration: ClinicalTrials.gov NCT00038649 NCT00048672 NCT00050531 NCT00129740 NCT00254423 NCT00333840.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Evaluable cytogenetic and molecular responses to different TKI modalities at 3- and 6-mo follow-up (imatinib 400, imatinib 800, nilotinib, and dasatinib). (A) Cytogenetic responses at 3 mo. (B) Molecular responses at 3 mo. * indicates that the majority of patients in the imatinib 400 group did not have molecular response values, as these patients were enrolled in the year 2000-2001, when PCR was not routinely done. (C) Cytogenetic responses at 6 mo. (D) Molecular responses at 6 mo.
Figure 2
Figure 2
EFS according to cytogenetic and molecular response at 3 and 6 mo. (A) EFS by cytogenetic response at 3 mo. (B) EFS by molecular response at 3 mo. (C) EFS by cytogenetic response at 6 mo. (D) EFS by molecular response at 6 mo. Molecular response analysis excludes patients treated with imatinib 400.
Figure 3
Figure 3
FFS according to cytogenetic and molecular response at 3 and 6 mo. (A) FFS by cytogenetic response at 3 mo. (B) FFS by molecular response at 3 mo. (C) FFS by cytogenetic response at 6 mo. (D) FFS by molecular response at 6 mo. Molecular response analysis excludes patients treated with imatinib 400.
Figure 4
Figure 4
TFS according to cytogenetic and molecular response at 3 and 6 mo. (A) TFS by cytogenetic response at 3 mo. (B) TFS by molecular response at 3 mo. (C) TFS by cytogenetic response at 6 mo. (D) TFS by molecular response at 6 mo. Molecular response analysis excludes patients treated with imatinib 400.
Figure 5
Figure 5
OS according to cytogenetic response at 3 and 6 mo. (A) OS by cytogenetic response at 3 mo. (B) OS by cytogenetic response at 6 mo.
See this image and copyright information in PMC

References

    1. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. [Abstract]. Blood. 2009;114(22):Abstract−1126.
    1. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018–1029. - PubMed
    1. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002;359(9305):487–491. - PubMed
    1. Saglio G, Kim DW, Issaragrisil S, et al. ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–2259. - PubMed
    1. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197–2203. - PubMed

Publication types

MeSH terms

Associated data